title: The Potential Societal Cost Benefits of Improved Inhalation Technique With Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbuhaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in Sweden.
authors.affiliation: Covance Inc., London, UK.
authors.forename: A
authors.initials: A
authors.lastname: Lewis
authors.affiliation: Covance Inc., London, UK.
authors.forename: M
authors.initials: M
authors.lastname: Blackney
authors.affiliation: Teva Pharmaceuticals Europe B. V, Amsterdam, The Netherlands.
authors.forename: S
authors.initials: S
authors.lastname: Torvinen
authors.affiliation: Teva Pharmaceuticals AB, Helsingborg, Sweden.
authors.forename: F
authors.initials: F
authors.lastname: Lindqvist
authors.affiliation: Teva Pharmaceuticals AB, Helsingborg, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Safioti
authors.affiliation: Parexel International, Stockholm, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Grundström
authors.affiliation: Parexel International, Stockholm, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Polyzoi
authors.affiliation: Teva Pharmaceuticals Europe B. V, Amsterdam, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Plich